Practical considerations in cancer-associated thrombosis
To improve prognosis of cancer patients, preventing venous thromboembolism is as essential as diagnosing and treating new clots
You will learn:
• The differences between cancer-associated thrombosis (CAT) and non-cancer venous thromboembolism (VTE)
• The VTE risk over time for patients with CAT
• Clinical trial and real-world evidence on the use of direct oral anticoagulants (DOACs) for the treatment of CAT
• Factors to consider when deciding between a DOAC and low-molecular-weight heparin for the treatment of CAT
• How cancer, CAT and the treatment of CAT affect quality of life.
WEBINAR HELD ON 1 June 2022
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.
To access this module, please register or login: